Breast cancer prognosis in Salah Azaiez Institute of Cancer, Tunis;Pronostic du cancer du sein à l'Institut de Carcinologie Salah Azaïez de Tunis

Eastern Mediterranean Health Journal

Volumn 13, Issue 2, 2007, Pages 309-318

  Ben Gobrane, H ^a   Fakhfakh, R ^a   Rahal, K ^b   Ben Ayed, F ^b   Maalej M ^b   Ben Abdallah, M ^b   Achour, N ^a   Hsairi, Med ^a  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICA; AGE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CENTER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROGNOSIS; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER CARE FACILITIES; FEMALE; HUMANS; INCIDENCE; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RESIDENCE CHARACTERISTICS; RISK FACTORS; RURAL HEALTH; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUNISIA; URBAN HEALTH;

EID: 34447284027     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Parkin DM et al. Cancer incidence in five continents, Vol. VII. Lyon, IARC, 1997 (IARC Scientific Publications, 143).
2. Boussen H, Bouaouina N, Rahal K. Hormonothérapie dans le cancer du sein. État des lieux en 2001. La Tunisie médicale, 2002,80:359-64.
3. Espié M. Dépistage de masse du cancer du sein: c'est efficace! La Revue du Praticien, 2001, 15:2101-4.
4. Hsairi M et al. Estimation à l'échelle nationale de l'incidence des cancers en Tunisie. 1993-1997. La Tunisie médicale, 2002, 80:57-64.
5. Ben Ahmed S et al. Pronostic du cancer du sein chez les femmes tunisiennes: Analyse d'une série hospitalière de 729 patientes. Santé publique, 2002, 14:231-41.
6. Chu KC et al. Recent trends in US breast cancer incidence survival, and mortality rates. Journal of the National Cancer Institute, 1996, 88:1571-9.
7. Ferlay J et al. Cancer incidence, mortality and prevalence worldwide. Lyon, International Agency for Research on Cancer, 2004.
8. Espié M. Traitement du cancer du sein. La Presse médicale, 1998, 12:1332-6.
9. Andrieu JM, Colonna P. Cancer du sein. Cancers : évaluation, traitement et surveillance. Paris, ESTEM, 1997.
10. Henderson B et al. Breast cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention, 2nd ed. New York, Oxford University Press, 1996.
11. Andersson I et al. Mammographic screening and mortality from breast cancer. The Malmo mammographic screening. British medical journal, 1988, 297:943-8.
12. Moss SM. Breast carcinoma mortality and screening. Cancer, 1997, 79:1-2.
13. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351:1451-67.
14. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 352:930-42.
15. Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Seminars in surgical oncology, 1989, 5:102-10.
16. Nemoto T et al. Breast cancer in the medial half; results of the 1978 national survey of the American College of Surgeons. Cancer, 1983, 51:1333-8.
17. Schechter AL et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 1984, 312:513-6.
18. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235:177-82.
19. Borg A et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer research, 1990, 50:4322-7.
20. Winstanley J et al. The long-term prognostic significance of c-erb-2 in primary breast cancer. British journal of cancer, 1991, 63:447-50.
21. Paterson MC et al. Correlation between c-erb-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer research, 1991, 51:566-7.
22. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer research, 1991, 51:944-8.
23. Groupe Registre du cancer du Nord de la Tunisie. Incidence des cancers dans le Nord de la Tunisie en 1994. Tunis, Institut de carcinologie, 2000:84.
24. Hsairi M et al. Rôle du médecin généraliste dans la lutte contre le cancer. La Tunisie Médicale, 2003, numéro spécial congrès maghrébin-Alger 24-25-26 février 2003:63-6.
25. e Congrès Mědical Maghrébin, Tunis, 19-21 mai 1997.
26. Khedhaier A et al. Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. British journal of cancer, 2003, 89(8):1502-7.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume II- The design and analysis of cohort studies. Lyon, International Agency for Research on cancer, 1987:456.
28. Sant M et al. The Eurocare working group. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. International journal of cancer, 2003, 106:416-22.
29. Coleman MP et al. The Eurocare Working Group. Eurocare-3, summary: cancer survival in Europe at the end of the 20th century. Annals of oncology, 2003, 14(Suppl. 5): v128-49.
30. Hsairi M et al. Connaissances, attitudes et comportements des femmes vis-à-vis du dépistage du cancer du sein. La Revue de Santé de la Méditerranée orientale, 2003, 9:87-98.
31. Chan A et al. Breast cancer in women < or = 35 years: review of 1002 cases from a single institution. Annals of oncology, 2000, 10:1255-62.
32. Jmor S, AI Sayer H, Heys SD. Breast cancer survival in women aged 35 and under: prognosis and survival. Journal of the Royal College of Surgeons of Edinburgh, 2002, 47:693-9.
33. Nixon AJ et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. Journal of clinical oncology, 1994, 12:888-94.
34. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? Journal of the National Cancer Institute. Monographs, 1994, 16:35-42.